China Approves World's First Invasive Brain Implant NEO
Chinese regulators have given the green light for commercial use of Neuracle Technology's NEO implant, which reads signals from the brain's surface and allows paralyzed patients to move their hands. This is the world's first invasive brain-computer interface approved for widespread use outside clinical trials.
China's 'Quantum Leap' in BCI: Why NEO Approval Is a Turning Point for the Entire Neurotechnology Industry
Analytical Note: Insights You Won't Find in Press Releases
June 3, 2026
Introduction
While global media buzzes with headlines about AI mergers or the latest electric vehicle prototypes, an event I call a 'tectonic plate shift' in medical technology has occurred. China has officially approved the mass commercial use of Neuracle Technology's invasive NEO implant. Formally, it's just a regulatory decision. Informally, it's the moment the US lost its monopoly on the 'arms race' in neural interfaces.
I've been running this blog long enough to remember when Elon Musk's Neuralink seemed like the only player in the game. But while Musk entertained the public with a pig playing Pong with its mind, China quietly, methodically, and with massive state support did what no one in the West could: brought a product to the real market outside clinical trials. Let's break down what's really behind this coin.
[The Core]: What's Really Happening
We're constantly told about the 'tech race' between the US and China in chips and AI. But that competition has moved to a new level—neural interfaces (BCI). The point isn't that the Chinese have a new toy. The point is they've changed the paradigm itself: BCI is no longer a lab curiosity; it's become a commercial medical service.
Notice the details: NEO isn't implanted directly into the brain cortex like Neuralink's chips. It sits on the dura mater. From a medical and legal standpoint, this is a genius move. China's regulator, the NMPA, didn't wait for the technology to become perfect. It approved what already works and carries a lower risk of hemorrhage and tissue scarring. It's 'good enough' instead of 'perfect but never.'
For the patient, this means a simple thing: surgery takes 90 minutes, and after 9 days of training, a paralyzed person can clench their hand. For the market, it means the entry barrier has collapsed. While the US, through the FDA, spends years gathering data for 'breakthrough devices,' China has already started assigning insurance codes to these implants under the mandatory health insurance system.
This isn't just news—it's a precedent. Now any investor sees that a technology that was futuristic 10 years ago is generating revenue right now.
Timeline and Context
To understand the scale, you need to look at the calendar a few months back. This isn't a spontaneous decision but the result of a planned state campaign.
In March 2026 (just three months before now), China's 15th Five-Year Plan was released. For the first time, BCI was named a 'key industry of the future' alongside quantum technologies and humanoid robots. And just days after that announcement, on March 13, the NMPA issued the 'world's first registration certificate' for an invasive BCI.
I remember how colleagues from Western venture capital funds dismissed Chinese developments in 2024, calling them 'copies.' But the numbers tell a different story. At the time of approval, Neuracle had conducted 36 clinical trials. For comparison, Neuralink at the same period had only about a dozen successful implants. China bet on quantity. They have 374,000 potential patients with spinal cord injuries—a huge data collection base.
Moreover, just last week (late May 2026), these implants began receiving unique codes for inclusion in the insurance system. This means the state is ready to pay for this technology. In the US, getting Neuralink into Medicare would require years of lobbying.
Who Wins and Who Loses
Let's go through the pockets.
Winner #1: China's Biotech Sector. Stocks of companies like Neuracle and BrainCo (a Pudong-based unit) have already risen, but the real explosion will happen when shipments begin. Currently, about 10 BCI companies are gathered in Pudong, and the region's biopharmaceutical production volume has reached nearly $70 billion.
Winner #2: Patients. It sounds cliché, but it's true. According to People's Daily, patients show not just control over a robotic glove but signs of neuroplasticity—the brain learns to use hands again even without the glove. One patient was able to write the word 'thank you' after a year—a breakthrough in rehabilitation.
Loser: Elon Musk's Neuralink. Despite claims of mass production in 2026, NEO is already 1-2 years ahead in regulatory status in China. Moreover, the Chinese market (the world's largest in terms of potential patients) is now effectively closed to Neuralink. Losing China means losing millions of dollars in future revenue.
Loser: European Regulator. While the EMA will be developing ethics committees, Chinese chips will already be in mass production. Europe risks becoming a museum of medical technology, buying solutions from China or the US.
What the Media Isn't Saying
Here's where it gets interesting. What press releases are silent about.
Insight #1: Neural Data as the New Oil.
Everyone discusses the medical aspect. But NEO collects millions of bits of real-time data on human brain activity. Neuracle and Tsinghua University now have access to the brain physiology of hundreds of patients. This data is invaluable. It will enable the next generation of AI models that understand humans without words. While Western companies fight over text data for LLMs, China is collecting 'raw' neural signals. The privacy issue of such data is not even raised in local discourse—it's a gray area that provides a huge advantage.
Insight #2: 'Reverse Engineering' the Brain.
Many experts (including those I've spoken with at MIT Technology Review) point out that NEO is less invasive—that's its plus. But from an engineering standpoint, it's also a limitation. It reads signals worse than Neuralink's direct needles. However, the Chinese are already working on 'Beinao II' (北脑二号)—a high-channel implant with a thousand channels. China's strategy is: launch the 'simple' version, fine-tune logistics, surgery, and production, and when version 2.0 arrives, simply replace old modules with new ones using the already established patient base.
Insight #3: 6G Geopolitics.
In documents supporting the BCI industry in China, BCI is grouped with 6G and humanoid robots. Imagine a future soldier controlling a drone or air defense system with their mind through such a chip. The defense potential of this technology, legalized under the guise of medical rehabilitation, is enormous. The US understands this, but it lacks the hospitalization system and unified patient database to test these scenarios at such scale.
Forecast: Next 30 Days and 90 Days
Looking at the situation without adjusting for Chinese speed is a rookie mistake. In China, a week can equal a year of Western progress.
Next 30 Days (July 2026):
Expect mass contracts with rehabilitation centers in the provinces. Neuracle already has production capacity in Pudong. I predict that within a month, NEO will appear in at least 50 major hospitals outside Beijing and Shanghai. Also, expect an announcement of funding from the China Brain Project (China's equivalent of the US BRAIN Initiative). We're talking about funds of around $3-5 billion, to be distributed among dozens of BCI startups like NeuroXess and StairMed.
Next 90 Days (September-October 2026):
Here's where the most interesting part happens. Expect the first official merger and acquisition (M&A) deal. Either a major Chinese tech giant (Huawei, Tencent, or Xiaomi, which already have medical divisions) will buy one of the developers of 'non-invasive' BCI headsets, or Neuracle will go public on the STAR Market. Neuracle's valuation now, according to unofficial data, hovers around $2-3 billion. After demonstrating the effectiveness of insurance payouts, that figure will double.
Additionally, panic will start at Western biotech conferences. Shares of Synchron (US) and other Neuralink competitors could drop 10-15% when investors see that Chinese bureaucracy works like a rocket, while Western bureaucracy works like a ferry.
The main risk I see: long-term biocompatibility. We don't yet have data on how these electrodes will behave after 5 years in the body. But China seems to be betting that even if the implant fails after 3 years, the patient will have undergone rehabilitation worth the money.
In summary: we have witnessed not just the approval of a gadget. We have witnessed Asia seizing the initiative in controlling the human body with machines. And it was done quietly, to the accompaniment of national anthems and the rustling of central bank notes. The West slept through this moment.
— Editorial Team
No comments yet.